2 top healthcare shares for growth investors right now

Are these the best healthcare stocks to buy for 2017?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today, I’m taking a look at two fast-growing healthcare shares. Biotech company Shire (LSE: SHP) has an excellent growth track record, boosted by a series of M&A transactions and internal drivers such as its successful innovation strategy and sound management. The firm has been able to succeed where others have failed by targeting the unmet medicals needs of those suffering from rare diseases through the development of highly specialised treatments.

Although the rare diseases market has a small target patient population, many patients suffer from debilitating, and often life-threatening conditions, which creates an opportunity for innovation. And given that there’s limited competition in the sector, Shire’s speciality medicines command high prices and generate phenomenal margins for the company. This explains why Shire’s near-40% adjusted EBIDTA margin compares very favourably to GlaxoSmithKline’s margin of around 25%.

That said, there are growing concerns that growth for the company is due to slow because of the tougher approvals requirements established by regulators in a bid to secure more favourable pricing and greater market access for patients. Shares in Shire have already lost around 12% of their value over the past month, but I feel the lower share price may provide a great opportunity to buy its shares at a discount.

Shares in Shire currently trade at 12.8 times its forecast 2016 earnings, a far cry from its five-year historical average of 20.6. This means that although growth may be about to slow, valuations seem to more than fully reflect that.

Fast-growing markets

Meanwhile, generic drugs maker Hikma Pharmaceuticals (LSE: HIK) benefits from its big exposure to fast-growing markets in the Middle East and North Africa. Its focus on affordable medicines in key therapeutic areas has earned it a strong market position in the MENA region, which uniquely positions the firm towards long-term sustainable growth as emerging markets begin to deliver on their expected potential.

The company’s shares have been on the slide for quite some time, and in November, sank to a 52-week low of 1,575p. That was after its disappointing first-half results, in which the Jordan-based firm reported a 32% fall in core earnings per share. Management remains sanguine though, as the fall in earnings was mostly due to the slower than expected approval process for a few of its new generic products in the first half. These products have since been approved, and so management expects its full-year results to be significantly weighted to the second half and has reiterated its full-year revenue guidance of $2.0 and $2.1bn.

Hikma does seem more expensive than Shire, with shares trading at 20 times its forecast earnings. However, that’s due to the delay in the approvals process, which will have a non-recurring impact on earnings this year. Looking further forward, valuations seem more reasonable – with shares in Hikma trading at just 14.7 times its 2017 earnings, as City analysts expect the firm to generate earnings per share of 117.6p in 2017.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jack Tang has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Would Warren Buffett buy BP shares, as oil excitement grows?

Warren Buffett is a big investor in the oil business, and BP's performance has been attracting investor attention in results…

Read more »

Cropped shot of an affectionate young couple posing with a bunch of flowers in their kitchen on their anniversary
Investing Articles

Here’s how long-term loyalty to UK shares can lead to dazzling returns!

The most successful UK and US share investors buy shares to hold for the long term, as this report shows.

Read more »

Investing Articles

NatWest has just smashed brokers’ dividend forecasts!

After NatWest delivered a Valentine’s Day surprise to investors, our writer thinks the experts may have to raise their dividend…

Read more »

Investing Articles

The NatWest share price slips in early trading despite positive FY 2024 results. What’s the deal?

The NatWest share price is down slightly this morning after the bank released its final results for 2024. Our writer…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

My Legal & General shares have climbed just 7% — so how come I’m sitting on a 20% gain?

Harvey Jones' trading account is showing only a modest return on his Legal & General Shares, but on drilling down…

Read more »

Investing Articles

Prediction: the BP share price could rise in 2025 (or it might fall!)

Following this week’s release of the energy giant’s 2024 results, our writer reviews the prospects for the BP (LSE:BP.) share…

Read more »

many happy international football fans watching tv
Investing Articles

What’s gone wrong with the FTSE 100’s ‘King of Trainers’?

Feeling the pain of a 28% drop in the JD Sports share price over the past three months, our writer…

Read more »

Investing Articles

Is it too late for investors to consider buying these outstanding FTSE 100 shares?

Stephen Wright wonders whether now's the time to consider buying shares in the FTSE 100’s outstanding companies, despite some high…

Read more »